MISONIX, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 22 rows in 2020. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2020-12-02: Reporting owner Waggoner Jonathan Jay; Form 4; Security Stock Option; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-11-30: Reporting owner Waggoner Jonathan Jay; Form 3; Security Stock Option; Transaction Holding.
- 2020-06-30: Reporting owner PATTON THOMAS M; Form 4; Security Stock Option; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-06-30: Reporting owner Vizirgianakis Stavros G.; Form 4; Security Stock Option; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2020-12-02 | Waggoner Jonathan Jay Officer (SVP, Wound Sales) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $13.66 exercise price | 2020-12-03 | |
| 2020-11-30 holding as of filing | Waggoner Jonathan Jay Officer (SVP, Wound Sales) | 3 | Stock Option Derivative · Direct | Holding | $13.57 exercise price | 2020-11-30 | ||
| 2020-06-30 | PATTON THOMAS M Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,060 3,060 owned after | $13.57 exercise price | 2020-07-02 | |
| 2020-06-30 | Vizirgianakis Stavros G. Director, Officer (CEO) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,995 50,995 owned after | $13.57 exercise price | 2020-07-02 | |
| 2020-06-30 | LAVIOLETTE PAUL A Director | 4 | Stock Option Derivative · Indirect · By SV Health Investors, LLC | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,060 3,060 owned after | $13.57 exercise price | 2020-07-02 | |
| 2020-06-30 | Staub Linwood A. Officer (Sr. VP Wound) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,998 4,998 owned after | $13.57 exercise price | 2020-07-02 | |
| 2020-06-30 | Klugewicz Sharon W Officer (Chief Operating Officer) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,079 4,079 owned after | $13.57 exercise price | 2020-07-02 | |
| 2020-06-30 | Watanabe Gwendolyn A Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,060 3,060 owned after | $13.57 exercise price | 2020-07-02 | |
| 2020-06-30 | Staley Allan Richard Officer (President) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,465 8,465 owned after | $13.57 exercise price | 2020-07-02 | |
| 2020-06-30 | Ludecker Robert S Officer (SVP Sales - Surgical) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,998 4,998 owned after | $13.57 exercise price | 2020-07-02 | |
| 2020-06-30 | Koby Michael Director | 4 | Stock Option Derivative · Indirect · By 1315 Capital Management, LLC | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,060 3,060 owned after | $13.57 exercise price | 2020-07-02 | |
| 2020-06-30 | Dwyer Joseph P Officer (Chief Financial Officer) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +13,564 13,564 owned after | $13.57 exercise price | 2020-07-02 | |
| 2020-05-14 | Dwyer Joseph P Officer (Chief Financial Officer) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +52,936 52,936 owned after | $9.82 exercise price | 2020-05-20 | |
| 2020-05-14 | PATTON THOMAS M Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,940 11,940 owned after | $9.82 exercise price | 2020-05-20 | |
| 2020-05-14 | Vizirgianakis Stavros G. Director, Officer (CEO) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +199,005 199,005 owned after | $9.82 exercise price | 2020-05-20 | |
| 2020-05-14 | Klugewicz Sharon W Officer (Chief Operating Officer) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,921 15,921 owned after | $9.82 exercise price | 2020-05-20 | |
| 2020-05-14 | Ludecker Robert S Officer (SVP Sales - Surgical) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +19,502 19,502 owned after | $9.82 exercise price | 2020-05-20 | |
| 2020-05-14 | LAVIOLETTE PAUL A Director | 4 | Stock Option Derivative · Indirect · By SV Health Investors, LLC | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,940 11,940 owned after | $9.82 exercise price | 2020-05-20 | |
| 2020-05-14 | Koby Michael Director | 4 | Stock Option Derivative · Indirect · By 1315 Capital Management, LLC | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,940 11,940 owned after | $9.82 exercise price | 2020-05-20 | |
| 2020-05-14 | Staub Linwood A. Officer (Sr. VP Wound) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +19,502 19,502 owned after | $9.82 exercise price | 2020-05-20 | |
| 2020-05-14 | Watanabe Gwendolyn A Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,940 11,940 owned after | $9.82 exercise price | 2020-05-20 | |
| 2020-05-14 | Staley Allan Richard Officer (President) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +33,035 33,035 owned after | $9.82 exercise price | 2020-05-20 |